The company manufactures customized cattle feed pellets for livestock owners and dairy farmers, primarily operating as a contract manufacturer for KSE Ltd using automated production facilities in Kerala.
The company lacks a durable moat as it operates primarily as a job-work contractor for a single major client, KSE Ltd. While it has significant production capacity, the declining revenue and negative EPS CAGR suggest a lack of pricing power and high dependency on the contract principal's formulations and demand.
Capital has been deployed toward maintaining aging facilities and paying out large chunks of cash for overdue preference dividends. The lack of growth reinvestment is reflected in the sharply negative revenue and earnings growth rates over time.
The company's reliance on a single client for job-work proved fatal as the principal's own demand softened, leaving Prima Agro with massive idle capacity and no independent brand to fall back on. The capital structure collapsed under the weight of unpaid preference dividends and interest obligations that the business could no longer service from its dwindling cash flows. Meanwhile, the substantial interest-free loans funneled to related parties were never recovered, draining the remaining liquidity and leaving the company a hollow shell of its former self.
RichFakir rates Prima Agro Ltd's business quality as poor — 20/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Prima Agro Ltd is trading about 31% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Prima Agro Ltd is: Not rated. A poor business at a cheap price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Prima Agro Ltd's fair value is about ₹21 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →